Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | HTR2A | P28223 | 9/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713891 | 1.00 | DRD2 (0.46) | DRD2HTR2AHTR7NPC1RAB9A | |
| SCHEMBL23175425 | 0.86 | DRD2 (0.46) | DRD2HTR2AHTR7HTR1A | |
| SCHEMBL14844353 | 0.83 | DRD2 (0.45) | DRD2HTR2AHTR7HTR1AHIF1A | |
| SCHEMBL7712271 | 0.83 | DRD2 (0.43) | DRD2HTR2AHTR7NPC1RAB9A | |
| SCHEMBL14844437 | 0.83 | DRD2 (0.43) | DRD2HTR2AHTR7NPC1RAB9A | |
| SCHEMBL14853326 | 0.83 | DRD2 (0.45) | DRD2HTR2AHTR7HTR1AHIF1A | |
| SCHEMBL17180607 | 0.81 | ACHE (0.56) | DRD2HTR2AHTR7 | |
| SCHEMBL12026856 | 0.78 | HIF1A (0.49) | DRD2HTR2AHTR7HTR1AHIF1A | |
| SCHEMBL3263185 | 0.76 | DRD2 (0.44) | DRD2HTR2AHTR7HTR1A | |
| SCHEMBL10637150 | 0.76 | DRD2 (0.50) | DRD2HTR2AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763997-B1 | CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9346824-B2 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists | HOFFMAN-LA ROCHE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140221350-A1 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221350-A1 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists | AVPR1A, AVPR1B, OXTR | DRD2 95/4885HTR2A 24/4885HTR7 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.